Status:
COMPLETED
Determination of Carboplatin's Optimal Plasmatic Exposure
Lead Sponsor:
Institut Claudius Regaud
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To determine Carboplatin's optimal exposures(optimal AUCs)and parameters they depend on.
Eligibility Criteria
Inclusion
- Carcinoma histologically proved and which must be treated by Carboplatin, excepted weekly administered Carboplatin treatments
- Age \> 18 years
- Neutrophils \> 1500/mm3, blood-platelets \> 100000/mm3
- Patient with intravenous administration route for chemotherapy independent of the one used for blood samples ( for Investigators centers achieving pharmacokinetic examination)
- Well-informed written consent, signed by the patient
Exclusion
- Carboplatin treatment's contra-indication
- Patient with clinically detectable cerebral metastasis
- Pregnant or nursing women
- Patient under guardianship or trusteeship
- Patient whose venous status don't permit a peripheral intravenous administration route's placing (for Investigators centers achieving pharmacokinetic examination)
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2009
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00145028
Start Date
May 1 2005
End Date
February 1 2009
Last Update
March 18 2009
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Paul Papin
Angers, France
2
Institut Bergonié
Bordeaux, France
3
Clinique Pasteur
Évreux, France
4
CHU A. Michallon
Grenoble, France